Silvia Rivara

List of Publications by Year in Descending Order

124 papers	4,076 citations	37 h-index	58 g-index
131 ext. papers	4,506 ext. citations	5.8 avg, IF	4.87 L-index

#	Paper	IF	Citations
124	In silico drug discovery of melatonin receptor ligands with therapeutic potential.. *Expert Opinion on Drug Discovery*, **2022**, 1-12	6.2	1
123	New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators. *Molecules*, **2021**, 26,	4.8	2
122	N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. *ChemMedChem*, **2021**, 16, 3071-3082	3.7	3
121	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. *European Journal of Medicinal Chemistry*, **2021**, 221, 113529	6.8	1
120	A sulfonyl fluoride derivative inhibits EGFR by covalent modification of the catalytic lysine. *European Journal of Medicinal Chemistry*, **2021**, 225, 113786	6.8	4
119	Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors.. *Journal of Chemical Information and Modeling*, **2021**,	6.1	3
118	Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. *European Neuropsychopharmacology*, **2020**, 32, 77-87	1.2	7
117	The Control of Heparanase Through the Use of Small Molecules. *Advances in Experimental Medicine and Biology*, **2020**, 1221, 567-603	3.6	5
116	Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. *Journal of Medicinal Chemistry*, **2020**, 63, 1261-1280	8.3	3
115	N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations. *ACS Catalysis*, **2020**, 10, 11797-11813	13.1	8
114	Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria. *Molecules*, **2020**, 25,	4.8	3
113	New classes of potent heparanase inhibitors from ligand-based virtual screening. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 1685-1696	5.6	4
112	Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations. *Methods in Molecular Biology*, **2020**, 2114, 307-337	1.4	7
111	New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an BRET-Based Discovery Platform. *ACS Chemical Biology*, **2019**, 14, 1727-1736	4.9	7
110	Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. *Journal of Pharmacy and Pharmacology*, **2019**, 71, 1762-1773	4.8	4
109	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. *European Journal of Medicinal Chemistry*, **2019**, 162, 507-524	6.8	8
108	Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands. *Journal of Medicinal Chemistry*, **2018**, 61, 3726-3737	8.3	11

107	Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 6918-6936	8.3	22
106	Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. *Journal of Medicinal Chemistry*, **2018**, 61, 7902-7916	8.3	10
105	Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 10834-10859	8.3	15
104	Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychological-cardiac comorbidity?. *Neuroscience and Biobehavioral Reviews*, **2017**, 74, 444-452	9	12
103	Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. *Journal of Chemical Information and Modeling*, **2017**, 57, 159-169	6.1	37
102	Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs. *Journal of Medicinal Chemistry*, **2017**, 60, 4304-4315	8.3	10
101	Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates. *Psychoneuroendocrinology*, **2017**, 82, 155-163	5	31
100	Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. *Journal of Medicinal Chemistry* , **2017**, 60, 787-796	8.3	21
99	Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). *Chemical Communications*, **2017**, 53, 12814-12817	5.8	20
98	Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. *Oncotarget*, **2017**, 8, 68338-68353	3.3	32
97	Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. *Scientific Reports*, **2016**, 6, 31046	4.9	6
96	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. *Journal of Medicinal Chemistry*, **2016**, 59, 6387-406	8.3	46
95	Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return. *Chemistry - A European Journal*, **2016**, 22, 8048-52	4.8	12
94	Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. *Glycobiology*, **2016**, 26, 640-54	5.8	51
93	Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. *Future Medicinal Chemistry*, **2016**, 8, 647-80	4.1	109
92	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. *Journal of Medicinal Chemistry*, **2016**, 59, 4651-63	8.3	21
91	Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 425-41	6.8	33
90	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1247-66	6.8	42

89	[5]-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. *European Journal of Medicinal Chemistry*, **2015**, 103, 312-24	6.8	26
88	Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats. *European Neuropsychopharmacology*, **2015**, 25, 2157-69	1.2	23
87	Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. *Journal of Medicinal Chemistry*, **2015**, 58, 7512-25	8.3	31
86	New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization. *European Journal of Medicinal Chemistry*, **2015**, 103, 370-3	6.8	11
85	Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. *Molecules*, **2015**, 20, 17132-51	4.8	4
84	Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. *PLoS ONE*, **2015**, 10, e0128699	3.7	20
83	Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential. *Journal of Medicinal Chemistry*, **2015**, 58, 4998-5014	8.3	27
82	Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 1145-56	5.5	10
81	Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide. *Journal of Chemical Information and Modeling*, **2015**, 55, 589-99	6.1	33
80	Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety. *Scientific Reports*, **2015**, 5, 18218	4.9	17
79	Towards the development of 5-HT[1] ligands combining serotonin-like and arylpiperazine moieties. *European Journal of Medicinal Chemistry*, **2014**, 80, 8-35	6.8	7
78	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. *Journal of Medicinal Chemistry*, **2014**, 57, 3161-85	8.3	112
77	Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate. *Organic and Biomolecular Chemistry*, **2014**, 12, 1561-9	3.9	15
76	Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. *Journal of Chemical Information and Modeling*, **2014**, 54, 2621-6	6.1	11
75	ST7612AA1, a thioacetate-[1]lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8358-77	8.3	31
74	Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands. *International Journal of Molecular Sciences*, **2014**, 15, 16114-33	6.3	6
73	Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods. *Advances in Protein Chemistry and Structural Biology*, **2014**, 96, 219-34	5.3	3
72	UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. *British Journal of Pharmacology*, **2014**, 171, 5195-208	8.6	31

71	Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. *Journal of Chemical Information and Modeling*, **2013**, 53, 821-35	6.1	28
70	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5290-4	2.9	2
69	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 2936-47	8.3	40
68	Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 1247-61	8.3	35
67	Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 2500-12	8.3	28
66	Homology models of melatonin receptors: challenges and recent advances. *International Journal of Molecular Sciences*, **2013**, 14, 8093-121	6.3	27
65	Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. *Molecules*, **2013**, 18, 13043-60	4.8	12
64	Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. *European Journal of Medicinal Chemistry*, **2012**, 48, 214-30	6.8	10
63	MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. *ChemMedChem*, **2012**, 7, 1954-64	3.7	21
62	Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2012**, 39, 318-25	3.5	46
61	Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. *Journal of Medicinal Chemistry*, **2012**, 55, 2251-64	8.3	48
60	N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. *Journal of Medicinal Chemistry*, **2012**, 55, 4824-36	8.3	44
59	Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. *Journal of Medicinal Chemistry*, **2011**, 54, 8362-72	8.3	22
58	Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. *Journal of Neuroscience*, **2011**, 31, 18439-52	6.6	87
57	Melatonin receptor agonists: new options for insomnia and depression treatment. *CNS Neuroscience and Therapeutics*, **2011**, 17, 733-41	6.8	50
56	Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. *European Journal of Medicinal Chemistry*, **2011**, 46, 4466-73	6.8	16
55	Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4910-6	3.4	13
54	Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. *Chemical Communications*, **2011**, 47, 2517-9	5.8	21

53	Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. *Mini-Reviews in Medicinal Chemistry*, **2011**, 11, 1019-30	3.2	36
52	Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure. *Advances in Protein Chemistry and Structural Biology*, **2011**, 85, 1-26	5.3	10
51	Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 1059-77	6.8	47
50	Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. *Journal of Medicinal Chemistry*, **2010**, 53, 2038-50	8.3	44
49	Structural Fluctuations in Enzyme-Catalyzed Reactions: Determinants of Reactivity in Fatty Acid Amide Hydrolase from Multivariate Statistical Analysis of Quantum Mechanics/Molecular Mechanics Paths. *Journal of Chemical Theory and Computation*, **2010**, 6, 2948-60	6.4	53
48	Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 5770-81	8.3	49
47	Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. *ChemMedChem*, **2009**, 4, 1495-504	3.7	32
46	N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. *ChemMedChem*, **2009**, 4, 1746-55	3.7	25
45	The collisional behavior of ESI-generated protonated molecules of some carbamate FAAH inhibitors isosteres and its relationships with biological activity. *Journal of Mass Spectrometry*, **2009**, 44, 561-5	2.2	4
44	Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 639-43	2.9	94
43	Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20966-71	11.5	179
42	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. *Journal of Medicinal Chemistry*, **2008**, 51, 3487-98	8.3	59
41	Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. *Current Topics in Medicinal Chemistry*, **2008**, 8, 954-68	3	54
40	Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 9911-24	3.4	29
39	Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. *Chemical Communications*, **2008**, 214-6	5.8	58
38	Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). *Annali Di Chimica*, **2007**, 97, 887-94		16
37	Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. *ChemMedChem*, **2007**, 2, 1741-9	3.7	11
36	Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate FAAH inhibitors. *Journal of Mass Spectrometry*, **2007**, 42, 1624-7	2.2	8

35	URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. *Chemistry and Biology*, **2007**, 14, 1357-65		86
34	N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. *Journal of Medicinal Chemistry*, **2007**, 50, 6618-26	8.3	70
33	Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. *ChemMedChem*, **2006**, 1, 130-9	3.7	53
32	Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 318, 563-70	4.7	76
31	Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. *Journal of Medicinal Chemistry*, **2006**, 49, 7393-403	8.3	24
30	Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4063-7	2.9	24
29	Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 1413-24	3.4	25
28	Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3383-91	3.4	26
27	MT2 selective melatonin receptor antagonists: design and structure-activity relationships. *Arkivoc*, **2006**, 2006, 8-16	0.9	12
26	Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. *Journal of Medicinal Chemistry*, **2005**, 48, 4049-60	8.3	72
25	Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 5647-57	3.4	39
24	Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. *Nature Neuroscience*, **2005**, 8, 1139-41	25.5	193
23	Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors. *Chemistry and Biodiversity*, **2005**, 2, 1438-51	2.5	8
22	Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. *European Journal of Pharmaceutical Sciences*, **2004**, 23, 89-98	5.1	13
21	Cyclohexylcarbamic acid 3S or 4Ssubstituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. *Journal of Medicinal Chemistry*, **2004**, 47, 4998-5008	8.3	239
20	Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 663-74	3.4	38
19	Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 3763-82	3.4	18
18	Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. *Journal of Medicinal Chemistry*, **2004**, 47, 4202-12	8.3	30

17	The role of HB-donor groups in the heterocyclic polar fragment of H3-antagonists. I. Synthesis and biological assays. *Il Farmaco*, **2003**, 58, 891-9		8
16	Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 3965-73	3.4	25
15	Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *Journal of Medicinal Chemistry*, **2003**, 46, 2352-60	8.3	151
14	Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. *Journal of Medicinal Chemistry*, **2003**, 46, 1429-39	8.3	53
13	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. *Drug Design and Discovery*, **2003**, 18, 65-79		6
12	Strategies leading to MT2 selective melatonin receptor antagonists. *Advances in Experimental Medicine and Biology*, **2003**, 527, 577-85	3.6	1
11	Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group. *Drug Design and Discovery*, **2003**, 18, 65-79		1
10	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. *Drug Design and Discovery*, **2003**, 18, 65-79		
9	Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 1045-57	3.4	44
8	2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists. *Journal of Medicinal Chemistry*, **2001**, 44, 2900-12	8.3	53
7	Structure-property relationships on histamine H3-antagonists: binding of phenyl-substituted alkylthioimidazole derivatives to rat plasma proteins. *Il Farmaco*, **2000**, 55, 239-45		1
6	Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups. *Il Farmaco*, **2000**, 55, 27-34		8
5	Experimental and theoretical analysis of the interaction of (+/-)-cis-ketoconazole with beta-cyclodextrin in the presence of (+)-L-tartaric acid. *Journal of Pharmaceutical Sciences*, **1999**, 88, 599-607	3.9	30
4	2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3624-34	8.3	96
3	Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. *Journal of Medicinal Chemistry*, **1998**, 41, 3831-44	8.3	67
2	H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. *Journal of Medicinal Chemistry*, **1997**, 40, 2571-8	8.3	19
1	Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. *Journal of Medicinal Chemistry*, **1997**, 40, 1990-2002	8.3	65